CEVI Share Price Performance
SEK 0
-165.20 (-100.00%)
Price SEK 0
Fair ValueSEK 160.00
Share Pricen/a
Narrative Update • Jul 21
CellaVision AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
CEVI Community Narratives
AN
Fair Value
·Fair Value SEK 160 4.8% undervalued intrinsic discount
Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 179 14.9% undervalued intrinsic discount
Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
Fair Value
·Fair Value SEK 180 15.3% undervalued intrinsic discount
Digital Cell Analysis And New Applications Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications
CellaVision’s growth story leans on labs moving to more connected, digital workflows and on new software that could make its instruments more useful day to day. But heavy exposure to government buying cycles in Europe and reliance on a key distribution partner could keep sales lumpy and delay the payoff from new products.Read more
AN
SEK 160
4.8% undervalued intrinsic discount
Fair Value
Revenue
9.89% p.a.
Profit Margin
21.33%
Future PE
20.73x
Price in 2029
SEK 181.8
Digital Cell Analysis And New Applications Will Drive Long Term Upside Potential
Hospital labs are steadily moving from manual microscope work to digital tools, and CellaVision aims to ride that shift with faster software, new bone marrow testing, and a push into nearby diagnostic areas. But the story depends on smooth distributor demand, public healthcare spending, and getting new products approved and adopted.Read more
AN
SEK 180
15.3% undervalued intrinsic discount
Fair Value
Revenue
11.09% p.a.
Profit Margin
24.18%
Future PE
20.17x
Price in 2029
SEK 204.77
Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets
CellaVision is getting ready to launch a bone marrow analysis add‑on and push further into Asia-Pacific, which could open new types of lab customers and lift repeat sales from software and reagents. The catch is that recent growth may be flattered by one-off shipments, slower installations, and product quality hiccups that could make results bumpier than they look today.Read more
AN
SEK 179
14.9% undervalued intrinsic discount
Fair Value
Revenue
9.67% p.a.
Profit Margin
21.53%
Future PE
23.42x
Price in 2029
SEK 203.71
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
CEVI: Fair Value View Will Balance CEO Transition And Recent Downgrade
Fair Value: SEK 160 4.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CEVI: New Leadership And Higher Margins Will Support Future Upside
Fair Value: SEK 180 15.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CEVI: New Leadership And Stable Margins Will Support Future Upside
Fair Value: SEK 179 14.9% undervalued intrinsic discount
15 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CellaVision AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 29, 2026
- 5.41
- 68.71%
- 17.46%
- 5.9%
About CEVI
- Founded
- 1994
- Employees
- 251
- CEO
- WebsiteView website
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
